A potential target for experimental drugs that block PRMT5—a naturally occurring enzyme some tumors rely more on for survival—has been identified by researchers with the Fralin Biomedical Research Institute’s Cancer Research Center in Washington, D.C.
This article was originally published on MedicalXpress.com